

Program

Default Venue: ROOM A

Day 1: Friday, April 10

8:25–8:30 Opening Remarks

Session1: Advances in Local Treatment of Breast Cancer: Optimization and De-escalation

Chairs: K. Shimazu – Japan and M. Yoshimura– Japan

- 8:30–8:50 Advances in Local Treatment of Breast Cancer: Optimization and De-escalation (I Jatoi–USA)
- 8:50–9:10 Modern Breast Radiotherapy: Less, Shorter, Smarter (Y Ono –Japan)
- 9:10–9:30 De-escalation Strategies of Local Treatment for Breast Cancer (Y Sagara–Japan)
- 9:30–9:50 Omission of Breast Surgery in Early Breast Cancer: Expanding Frontiers in DCIS and Post–Neoadjuvant Complete Response (T Shien–Japan)
- 9:50–10:10 Discussion and Voting

Session2: Advances in Axillary Management of Breast Cancer: Optimization and De-escalation

Chairs: C. Yamauchi–Japan and S. Imoto – Japan

- 10:20–10:45 De-escalation of axillary surgery – optimization of management (J R Benson–UK)
- 10:45–11:10 Evolution and Optimization of Axillary Surgery in Breast Cancer (M Inokuchi–Japan)
- 11:10–11:35 Optimization and De-escalation of Regional Nodal Irradiation and Radiation Treatment Considerations in the Era of Axillary Surgical De-escalation (R Jagsi–USA)
- 11:35–12:00 Discussion and Voting

Sponsored Seminar 1: Co-organized by CHUGAI PHARMACEUTICAL CO.,LTD

- 12:10–12:50 The Evolution of HER2–Targeted Therapy: Where We Came From and Where We Are Going (T Aruga–Japan) **Chair: M. Takada – Japan**

Sponsored Seminar 2 (ROOM B1): Co-organized by Guardant Health Japan Corp.

12:10–12:50 Liquid Biopsy for Personalized Breast Cancer Management: Current Evidence and Future Perspectives (M Kawashima–Japan) **Chair: T. Sugie –Japan**

Session3: Neoadjuvant Therapy and Local Treatment

Chairs: J. Watanabe–Japan and M. Miyashita – Japan

13:00–13:20 (G Curigliano–Italy)

13:20–13:40 Redefining Perioperative Treatment After KEYNOTE–522 – Immunotherapy, ADCs, and Treatment Individualization (H Rugo–USA)

13:40–14:00 (M Kok–Netherlands)

14:00–14:40 Discussion and Voting

Sponsored Seminar 3: Co-organized by Daiichi–Sankyo Co., Ltd.

14:50–15:30 Treatment Strategies Using Antibody–Drug Conjugates (ADCs) in HR–positive/HER2–Negative Metastatic Breast Cancer (H Masuda–Japan)

Chair : K. Matsumoto–Japan

Sponsored Seminar 4 (ROOM B1): Co-organized by Pfizer Japan Inc.

14:50–15:30 New Treatment Strategies for HER2–Positive Metastatic Breast Cancer in Japan (J Tsurutani–Japan) **Chair: T. Nakayama**

Session4: Tailoring Treatment Intensity in HR+/HER2– Early Breast Cancer

Chairs: S. Saji–Japan and M. Takada–Japan

15:40–16:00 (N Harbeck–Germany)

16:00–16:20 Tailoring Treatment Intensity in HR+/HER2– Early Breast Cancer: Japan–Initiated Trials in the Global Landscape (H Masuda–Japan)

16:20–16:40 Update in Multigene Assays and cfDNA Analysis in Early Breast Cancer (W Han–South Korea)

16:40–17:20 Discussion and Voting

Day 2: Saturday, April 11

Session5: Title: Translating Biomarkers into Practice: From ctDNA-MRD to Tumor-Immune Profiling in Breast Cancer

Chairs: T. Sugie-Japan and T. R. Kataoaka-Japan

- 8:30-8:55 MRD-guided personalized treatment in early breast cancer (T Ueno-Japan)
- 8:55-9:20 Spatial biomarkers for anti-HER2 ADCs (D Ma-China)
- 9:20-9:45 Clinical Translation of the Breast Tumor-Immune Landscape to your Daily Practice. (R Salgado-Belgium)
- 9:45-10:10 Discussion and Voting: Presenters listed above and S Fox-Australia

Sponsored Seminar 5: Co-organized by Eli Lilly Japan K.K.

- 10:20-11:00 Recent Advances in Breast Cancer Systemic Therapy: Focus on Key Topics (Y Naito-Japan) Chair: W Tsuji - Japan

Sponsored Seminar 6 (ROOM B1): Co-organized by Sojitz(China) Co., Ltd.

- 10:20-11:00 AI Powered Ultrasound Screening for Breast Cancer (M Kataoaka-Japan)
Chair: M Toi - Japan

Session6: Reimagining the Future: A New Era of Breast Cancer Screening and Risk Prediction

Chairs: M Toi - Japan and M Kataoaka - Japan

- 11:10-11:30 Reimagining Breast Cancer Screening: Implementing Risk-Based Strategies for Japanese Women in the Era of AI and Genomics (H Yamauchi-USA)
- 11:30-11:50 Artificial Intelligence for Breast Cancer Risk Prediction in Asian Populations (G Lin-Taiwan)
- 11:50-12:10 METIS Eye: Clinical Evidence and Real-World Cases - Can AI Serve as a "Second Eye"? - (M Takahashi-Japan)

- 12:10–12:30 Evolutionary histories of breast cancer and related clones(T Nishimura–Japan)
- 12:30–12:50 Discussion and Voting

Sponsored Seminar 7: Co-organized by Exact Sciences Corporation

- 13:00–13:40 Personalizing Perioperative Therapy in ER-Positive Breast Cancer: Current Strategies and Future Perspectives (K Kawaguchi–Japan) **Chair: N Masuda–Japan**

Sponsored Seminar 8 (ROOM B1): Co-organized by MSD K.K.

- 13:00–13:40 Perspectives on Local Therapy in the Era of Perioperative Immunotherapy (Y Maeshima–Japan) **Chair: Y Takahashi – Japan**

Consensus Sessions

- 13:50–15:20 Poster Award Ceremony
- Panel Consensus Session1
- 15:30–17:00 Panel Consensus Session2